- Home
- SSP vs ZNTL Comparison
SSP vs ZNTL Comparison
Compare SSP & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SSP | ZNTL |
|---|---|---|
| Founded | 1878 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.6M | 289.0M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SSP | ZNTL |
|---|---|---|
| Price | $3.11 | $4.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $6.95 | $6.60 |
| AVG Volume (30 Days) | 823.9K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,150,585,000.00 | N/A |
| Revenue This Year | $8.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.04 | $1.21 |
| 52 Week High | $5.39 | $6.95 |
Technical Indicators
Market Signals| Indicator | SSP | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 54.68 |
| Support Level | $2.09 | $3.53 |
| Resistance Level | $3.25 | $5.11 |
| Average True Range (ATR) | 0.22 | 0.44 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 80.41 | 62.02 |
Price Performance
Historical ComparisonAbout SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.